Treatment for non-Hodgkin's lymphoma (stage I, II) of the elderly: Usefulness of local and regional irradiation and reduced dose chemotherapy
| Autor: | Naoto Shikama, Koutarou Gomi, Shusuke Sone, Shigeru Sasaki, Masahiko Oguchi, Kazuyoshi Takei, Itaru Izuno |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Male
Cancer Research Vincristine medicine.medical_specialty Cyclophosphamide Prednisolone medicine.medical_treatment Leucovorin Bleomycin Gastroenterology chemistry.chemical_compound Recurrence Prednisone Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Radiology Nuclear Medicine and imaging Survival rate Aged Neoplasm Staging Aged 80 and over Chemotherapy Radiation business.industry Lymphoma Non-Hodgkin medicine.disease Combined Modality Therapy Lymphoma Non-Hodgkin's lymphoma Surgery Survival Rate Methotrexate Oncology chemistry Doxorubicin Female business Follow-Up Studies medicine.drug |
| Zdroj: | International Journal of Radiation Oncology*Biology*Physics. 37:87-92 |
| ISSN: | 0360-3016 |
| Popis: | Purpose: To examine the usefulness and safety of a new treatment regimen consisting of irradiation to the involved area and adjacent lymph node area, and reduced dose chemotherapy for elderly patients with non-Hodgkin's lymphoma. Methods and Materials: The core of this study was 38 elderly patients older than 65 years old with intermediate or high grade non-Hodgkin's lymphoma, and concomitantly suffering from some other geriatric disease. They received involved area irradiation (40 Gy), adjacent lymph node irradiation (30 Gy), and reduced dose chemotehrapy (two cycles of 50–70% ACOP: Doxorubicin, Cyclophosphamide, Vincristine, Prednisone or 70% MACOP-B: Doxorubicin, Cyclophosphamide, Vincristine, Methotrexate, Bleomycin, Prednisone for 4 weeks). Results: The completion rate of the treatment regimen was 100%. The 5-year local control rate was 98%. The 5-year disease-free survival rate and the 5-year cause-specific survival rate for all patients were 70 and 82%, respectively. No treatment deaths were observed, and the rate of serious complications arising from the treatment was 3%. Conclusions: The newly conducted treatment regimen proved to be safe and useful for elderly patients with non-Hodgkin's lymphoma concomitantly suffering from some other geriatric disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|